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Hemodialysis vascular access surveillance continues to be
widely recommended despite ongoing controversy as to its
benefit in prolonging access patency compared with clinical
monitoring alone. The most common screening tests are
access blood flow and dialysis venous pressure
measurements. When surveillance test results cross a
predetermined threshold, accesses are referred for
intervention with correction of stenosis to reduce future
thrombosis and prolong access survival. Current surveillance
strategies have four components: (1) underlying condition;
(2) screening test; (3) intervention; and (4) outcomes.
However, limitations exist within each component that
may prevent achieving the desired outcomes. This review
discusses these limitations and their consequences.
To date, randomized controlled trials have not consistently
shown that surveillance improves outcomes in grafts,
and there is limited evidence that surveillance reduces
thrombosis without prolonging the life of native fistulae.
In conclusion, current evidence does not support the concept
that all accesses should undergo routine surveillance with
intervention.
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In the years following the introduction of synthetic
arteriovenous grafts, hemodialysis patients frequently experi-
enced graft thrombosis and failure. The cycle of thrombosis,
thrombolysis with correction of stenosis, and thrombosis
was considered the natural order of things. This changed
when two paradigm-altering studies1,2 reported that dynamic
and static dialysis venous pressure (VP) measurements
combined with preemptive angioplasty yielded large reduc-
tions in thrombosis rates and replacement of vascular
accesses.
These reports led the National Kidney Foundation
Kidney Disease Outcomes Quality Initiative (NKF-KDOQI)
guidelines3,4 to recommend that grafts and native arteriove-
nous fistulae undergo routine surveillance for stenosis with
preemptive correction of the stenosis. Surveillance includes
device-based measurements, such as access blood flow (Qa)
and static (or derived static) VP. Surveillance is intended to
supplement clinical monitoring, which uses physical exam-
ination and other clinical evidence of access dysfunction,
such as difficult cannulation or prolonged bleeding post
dialysis. Dynamic VP has been largely discredited as a
surveillance strategy and is considered to be monitoring.4
The KDOQI Vascular Access Work Group4 applied an
evidence-based approach to develop the guidelines; however,
the lack of quality evidence in this field has led to
considerable debate over these guidelines.5–11 The contro-
versy follows from a growing body of evidence that
surveillance as usually practiced (i.e., monthly Qa measure-
ment) may not improve access outcomes, is costly, and
may even be harmful.6,8,9,12–15 However, there is a general
agreement that monitoring of accesses with physical
examination and clinical assessment should be part of the
standard care of all dialysis patients.
This paper will review the recommendations for access
surveillance, its rationale, and the controversy by evalua-
ting the four necessary components of the strategy of access
surveillance (Figure 1): the background condition, the
screening test, the intervention, and the outcome.
CURRENT RECOMMENDATIONS
In Qa surveillance, the KDOQI Guidelines4 recommend an
intervention referral when graft Qa iso600ml/min or when
Qa has decreased by 425% and falls below 1000ml/min.
Fistula referral is not recommended until Qa is
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o400–500ml/min because fistulae may remain patent at a
lower Qa than grafts. VP is normally adjusted for the mean
arterial pressure (VP/MAP) because an increase in MAP
causes VP to increase. Grafts or fistulae are referred if static
VP/MAP has increased to40.50 or derived static VP/MAP is
40.55. KDOQI4 recommends that Qa be measured monthly.
VP measurements are less complex. Therefore, static VP
measurements are recommended at least every 2 weeks,
whereas derived static VP measurements should be taken
every 1–2 weeks because the blood pump augments variation
in measurements.4 The Guidelines emphasize the importance
of using trend analysis to guide referral decisions rather than
relying on a single measurement. It is noteworthy that not all
national guidelines recommend the routine use of Qa
surveillance.16
RATIONALE FOR SURVEILLANCE
Grafts have a low early failure rate. However, they often
develop stenosis and subsequent thrombosis in the weeks and
months after surgery, most commonly at the venous
anastomosis or outflow vein. The stenotic lesion, referred
to pathologically as neointimal hyperplasia, is believed to
develop because of a combination of blood flow turbulence,
low or oscillatory shear stress, and endothelial dysfunc-
tion.17,18 Neointimal hyperplasia includes myointimal
proliferation, matrix deposition, infiltration with macro-
phages, and neovascularization.17,19 Active participants in
this process include vasoactive, thrombogenic, and mitogenic
factors, among which reactive oxygen species, inflammation,
and platelet aggregation are major components. The lesion
results in progressive stenosis and thrombosis and accounts
for most graft failure.
The frequent failure of established grafts has led to a
preference for fistulae that, once established, have lower
failure rates.3 However, fistulae also develop neointimal
hyperplasia,20–22 although the details of fistula failure differ
from grafts. Fistulae are not suitable for cannulation until
they have undergone a maturation process of dilatation and
remodeling of the vein. Poor vessel elasticity and vessel
calcification may cause maturation failure by preventing
adequate dilatation,23 which may be associated with hemo-
dynamic conditions that promote neointimal hyperplasia.
Thus, fistulae with maturation failure often develop stenosis
at the arteriovenous anastomosis or downstream vein.
Additional factors may contribute to stenosis. For example,
mobilization of the swing segment of the vein during surgery
may disrupt the vasa vasorum, leading to ischemic changes
that promote stenosis.24 Thus, although grafts may fail after
initially functioning adequately, as many as 60% of fistulae
may never be suitable for dialysis.25,26
The rationale for surveillance is based on the hypothesis
that progressive stenosis is accurately detected by reduced
Qa and increased VP before thrombosis and access loss.
Screening of these parameters, which are surrogates for
stenosis, is intended to detect stenosis before thrombosis
and allows for a corrective procedure such as angioplasty
to maintain the patency of the vascular access. Prevention
of thrombosis is beneficial because it avoids unscheduled
intervention procedures that may be accompanied by central
venous dialysis catheters, hospitalizations, and increased
costs of care.
SURVEILLANCE STRATEGY
In evaluating the validity and usefulness of a surveillance
strategy, it is useful to examine its four components (Figure 1)
by applying globally recognized criteria for screening tests
according to the World Health Organization.27
The condition
The undesired condition, thrombosis in a vascular access,
must be an important health issue. The epidemiology and
natural history of access thrombosis, including development
from latent to declared disease (i.e., stenosis leading to
thrombosis), should be adequately understood. In addition,
there should be a detectable risk factor, disease marker, latent
period, or early symptomatic stage. This latent period is
necessary to allow time for an intervention to be applied
so as to improve the outcome. Other relevant conditions
that should be considered in the surveillance strategy are
the natural history of the access following the interven-
tion and the pathophysiology that leads to ultimate access
abandonment.
The test
The screening test, Qa or VP measurements, must be simple,
safe, precise, unbiased, and validated with adequate reprodu-
cibility in detecting stenosis in appropriate populations. The
distribution of test values should be known and there should
be suitable threshold levels for intervention referral that are
well defined and agreed upon. A policy should be agreed
upon with regard to the further diagnostic investigation of
individuals with a positive test, in this case an angiogram, to
confirm the access stenosis.
Issues
The underlying natural history of
thrombosis and access loss is unclear
Condition
Issues
Accurate and reliable
screening tests?
Screening
Access flow (Qa)
Venous pressure (VP)
Issues
Benefit versus
potential harm
Intervention
Angioplasty
± stent
Issues
Validity of
clinical trials
Outcome
Thrombosis
Access survival
Figure 1 |Components of a surveillance strategy that
influence its validity and usefulness. The four components of
vascular access surveillance strategy are as follows: the underlying
condition, screening tests, referral for intervention procedures,
and outcome. Each component has issues that may affect success
of the surveillance strategy.
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The intervention
The intervention, angioplasty (þ / stenting) or surgical
revision, should be effective for patients identified through
early detection. There should be evidence that early treatment
leads to better outcomes compared with late or no treatment.
The intervention must be clearly defined and standardized to
ensure reproducibility.
The outcome
There should be evidence from high-quality randomized
controlled trials that the surveillance program is effective
both in reducing morbidity and in yielding the desired
outcomes. The opportunity cost of the screening strategy’s
program (including testing, diagnosis and treatment, admin-
istration, training, and quality assurance) should be econom-
ically balanced in relation to expenditure on medical care as a
whole. There should be a plan for managing and monitoring
the screening program and an agreed set of quality assurance
standards.
THE CONDITION
The natural history of access thrombosis and the impact of
intervention (angioplasty or thrombolysis) on the natural
history are unclear and under active research.28,29 However,
the conditions of the dialysis environment and its potential
impact on the screening test will be discussed.
Impact of access hemodynamics on surveillance
Role of vessel diameter. The screening test attempts to
detect stenosis by reliably detecting changes or abnormalities
in Qa or VP. Thus, mathematical models have been used to
improve the understanding of access hemodynamics and the
potential effectiveness of surveillance.23,30–32
The graft model, derived from duplex ultrasound studies
of 94 patients, includes the inflow artery, arterial and venous
anastomoses, graft, stenosis, and outflow vein.30,31 A key
characteristic of the model is the vessel luminal diameters,
which vary over a wide range; however, the artery was
generally narrower than the vein (median artery/vein
diameter ratio¼ 0.77). A narrow vessel mimics stenosis in
that it increases vascular resistance. Examination of these
models has shown that vessel diameters in the access circuit
predominantly control the relation between Qa or VP and
stenosis (Figure 2), and this can impair the accuracy of
surveillance.
Figure 3a and b show that the relationship between Qa
and stenosis in grafts is sigmoidal: as stenosis progresses, Qa
initially remains unchanged but then rapidly decreases as
critical stenosis is reached.30 Moreover, narrower arteries
cause a reduction in Qa and shift the curve to the right. Thus,
as stenosis progresses, there is a longer delay in the decrease
in Qa, followed by an even more rapid decrease in Qa at
critical stenosis. When translated into a clinical setting, the
duration of the delay, the magnitude of the Qa change, and
its relationship to access diameters (i.e., ‘the condition’) are
so poorly understood that it cannot be reliably applied to a
surveillance strategy.
Similar concerns and results are obtained with static VP.31
A relatively narrow artery will cause a delay in the increase in
VP with progressive stenosis, followed by a more rapid
increase in VP at critical stenosis. KDOQI recommends
referral for intervention when VP/MAP increases to 40.50,4
but this threshold occurs at stenoses ranging from 38 to 73%
Qa
Artery                Graft                 Vein
 VP
Venous dialysis needle
a
b
Figure 2 | Luminal diameters strongly influence blood flow
(Qa) and dialysis venous pressure (VP) in the vascular access
circuit. In (a), increasing artery luminal diameter reduces overall
circuit resistance, and thus graft Qa increases despite no change
in stenosis. Similarly, in (b), increasing artery luminal diameter
allows transmission of vascular pressure to the dialysis needle,
and thus VP increases. Thicker arrows represent larger values for
Qa and VP, but do not indicate relative numerical values.
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Figure 3 |Vessel diameters control relation between blood
flow (Qa) and stenosis. (a) Relationship between graft (Qa) and
stenosis at venous anastomosis.30 (b) Relationship between graft
Qa and stenosis at venous anastomosis, with Qa plotted as a
percentage of the initial value. For narrower arteries (lower artery/
vein diameter ratios), the sigmoid curve is flattened and shifted to
the right, causing delay and then rapid reduction in flow as
stenosis progresses. Dashed line shows that by the time Qa has
decreased by 25% (the Kidney Disease Outcomes Quality Initiative
(KDOQI) referral threshold4), flow is on the rapidly falling part of
the curve. Thus, standard monthly surveillance may fail
to detect a decrease in flow before thrombosis. High (1.28),
median (0.77), and low (0.40) artery/vein ratios derived from
94 patients; low and high ratios enclosed 95% of patients.
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(average 50%; Figure 4). Thus, VP does not indicate a
particular level of stenosis. Moreover, similar to Qa, a
relatively narrow artery will cause a delay in change followed
by a more rapid increase in VP/MAP at critical stenosis.
Hence, as vessel diameters control the relationship
between Qa or VP and stenosis, relatively narrow arteries
dominate circuit resistance until stenosis is well advanced.
Assuming stenosis progresses at a constant rate, Qa or VP
may change so rapidly that monthly Qa or twice monthly VP
measurements may not detect a change before thrombosis.
From a clinical standpoint, it would seem ideal for the
clinician to know the access’ diameter in relation to the rate
of change of Qa. Yet, how would this be practically known,
interpreted, and used? This highlights the complex relation-
ship between vessel diameter and Qa and our lack of true
understanding of the condition’s natural history, a requisite
in the criteria for using a screening test.
Hemodynamic variation during dialysis. Another issue
affecting surveillance measurements is the large hemody-
namic variation that occurs during dialysis when measure-
ments are taken.33 Consider that Qa is determined by MAP,
central venous pressure (CVP), and vascular resistance of
the access circuit (R) according to the following equation:
Qa¼ (MAPCVP)/R.30 All three variables rapidly change
during dialysis; therefore, Qa, the most common screening
measurement, is unstable. Figure 5 shows large variations in
MAP in two patients who were typical of a group of 51
patients.33 These hemodynamic variations explain the large Qa
changes that often occur within a single dialysis session
(Figure 6), and these variations may be even greater when
measured from session to session.34–37 Thus, a change in Qa
must be 433% in order to be significantly different from
background Qa variation at Po0.05.34 A reduction in Qa of
433% may be an adequate justification for an intervention
referral if the result is consistent with other clinical information.
Timing of surveillance measurements
The KDOQI4 recommends that surveillance measurements
be taken early in dialysis before ultrafiltration causes
hemodynamic changes in Qa or VP. However, hemodynamic
variation is generally not reduced early in a session;33,34
hence, this approach may be flawed. Moreover, higher
ultrafiltration volumes increase the risk of thrombosis in
the period between sessions when thrombosis usually
occurs.38 Hence, one could argue that measurements should
be taken late in a session when hemodynamics most closely
approximate the period following a session. In our opinion,
there are insufficient data to make a recommendation with
regard to timing of measurements.
To summarize, in terms of the World Health Organization
criteria, the conditions are imperfect. The needed latent
period that allows time for intervention is not always
available and the natural history of the access is not well
understood. Given the patient characteristics (e.g., vessel
sizes) and dialysis environments (e.g., hemodynamic varia-
bility), the screening test is not reliably reproducible. Even
when surveillance threshold values are met, some accesses
will not thrombose, whereas others will thrombose much
earlier than the threshold value, highlighting our lack of
understanding of the pathophysiology and our inability to
appropriately intervene, in order to reliably prevent access
thrombosis.
THE TESTS
The foregoing discussion indicates that access hemodynamics
may impair the ability of Qa and VP measurements to detect
stenosis and impair the ability to avoid false indications of
stenosis. How do monthly Qa and twice monthly VP
measurements hold up to the current standards for screening
tests ?27,39
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Figure 4 |Vessel diameters control relation between venous
pressure and stenosis. Relationship between static dialysis
venous pressure adjusted for mean arterial pressure (VP/MAP)
and stenosis at graft venous anastomosis.31 Dotted line at
VP/MAP¼ 0.50 indicates the Kidney Disease Outcomes Quality
Initiative (KDOQI) referral threshold.4 There is no consistent
relationship between VP/MAP and stenosis, and note the rapid
increase in VP/MAP when artery is narrower than vein. Artery/vein
ratios defined in Figure 3.
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Figure 5 |Blood pressure varies widely within and between
dialysis sessions. Mean arterial pressures (MAPs) of two
representative patients with grafts during seven consecutive
dialysis sessions (reprinted with permission from the National
Kidney Foundation).33 Note that large MAP variations occurred
throughout the sessions.
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Recommendations for screening tests are on a strong
ground if they are based on randomized controlled trials in
which a screened group is compared with a control group
that undergoes usual care.39 The problem with nonrando-
mized or observational studies is that, for a number of
reasons, they are biased toward finding a treatment
benefit.40–42 For example, historical control groups may not
be comparable to contemporary treatment groups that may
benefit from recent improvements in care. Also, more interest
and attention may be given to access issues in a treatment
group when clinicians are aware that they are working with a
new or potentially beneficial treatment under study.
The paradigm-altering studies1,2 were not randomized
controlled trials, and subsequent KDOQI surveillance
recommendations3 have been based upon studies that used
historical or nonconcurrent control groups. Consequently,
their statistical methods were not always appropriate for
evaluating the usefulness of screening tests. For example, the
influence of Qa on the relative risk of thrombosis was used to
justify surveillance.43–45 Although a low Qa is associated with
an increased risk of thrombosis, this association does not
ensure that the test has adequate accuracy in predicting
thrombosis.
In contrast, when receiver operating characteristic (ROC)
curves were used, Qa and VP surveillances were found to be
inaccurate predictors of graft thrombosis.46–50 For example,
Ram et al.50 studied 176 patients who underwent a total of
1957 monthly Qa measurements over 6 years. They evaluated
the accuracy of monthly Qa measurements, or percentage
decrease in Qa (DQa), in predicting thrombosis within the
next month. They found that Qa had a sensitivity of 80% at a
false-positive rate of 60% and DQa had a sensitivity of 81% at
a false-positive rate of 50%. The mean Qa in grafts that did
not thrombose the next month was 1345ml/min (range
90–4000), and the mean in grafts that did thrombose was
895ml/min (range 105–2115; Figure 7); hence, values over-
lapped widely. Moreover, the majority of thromboses were
not preceded by a DQa measurement, usually because
thrombosis occurred before a second measurement could
be taken. Thus, this study did not support routine
application of Qa surveillance to predict graft thrombosis.
It is important to avoid a ‘one size fits all’ approach to
screening tests as the risks and benefits of tests may vary
among different groups of patients and/or their accesses.
Thus, surveillance guidelines should consider differences in
risk of thrombosis. For example, Ram et al.50 found that
older grafts were unlikely to thrombose even at a low Qa,
indicating that a low Qa is not always associated with a high
risk of thrombosis. Older grafts with a large DQa were also
unlikely to thrombose, suggesting that these large decreases
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Figure 6 |Blood flow (Qa) varies widely within dialysis sessions. Histograms computed with data from four studies34–37 show large
percentage change in Qa (delta Qa) in grafts within single dialysis sessions.34 Changes were measured over periods ranging from 1 to 3 h by
three measurement methods. Positive values indicate decrease in flow; negative values indicate increase in blood flow. N, number.
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were likely caused by hemodynamic variation rather than by
increased stenosis. On the other hand, new grafts were far
more likely to thrombose in the near future.
Thus, the screening test should take into account the risks
associated with a particular population. In this example, graft
age should be considered when deciding whether to refer for
intervention, and referrals should not be based solely upon a
single Qa measurement. Further studies to determine high-
risk populations and how the surveillance strategy performs
in these populations will help focus the use of limited
resources.
THE INTERVENTION
The goal of a surveillance strategy is to correct access
dysfunction while avoiding significant harm. However, Ram
et al.50 showed that a high sensitivity in predicting
thrombosis requires a high false-positive rate that likely
yields many unnecessary intervention procedures. Further-
more, it has now been recognized that unnecessary
angioplasty of a stable or slowly growing stenotic lesion
may impair access survival. For example, Chang et al.51
showed that angioplasty causes an increase in cellular
proliferation that is associated with neointimal hyperplasia.
In fact, angioplasty is used to induce vessel wall intimal
hyperplasia and stenosis in order to study its pathophysiol-
ogy.52 Thus, surveillance-induced angioplasty may stimulate
aggressive re-stenosis.53–57 It is possible that the failure of
surveillance to prolong access survival in randomized
controlled trials has been caused by false-positive referrals
with unnecessary angioplasty procedures. Thus, surveillance
tests may fail the requirement that they do no harm.
Clarification of this issue will require standardization of
angioplasty procedures and documentation of outcomes.
However, it is unclear that such standardization has been
achieved among interventional nephrologists, radiologists,
and surgeons.58,59 Furthermore, studies that evaluate surveil-
lance should document the effectiveness of consequent
angioplasty.7 They should confirm that angioplasty has
yielded improvements in both access anatomy and in the
screening test measurements that have led to the interven-
tion. Moreover, they should define what constitutes a
successful angioplasty treatment. In the future, this may be
guided by research that validates clinically important
procedure-related outcomes.
In the meantime, new techniques are being evaluated that
may limit the challenges posed by angioplasty-related re-
stenosis and problematic elasticity of stenotic lesions. For
example, stent grafts are based on the concept that treatment
of stenosis with a stent covered with graft material may
prevent elastic recoil and tissue in-growth. Such an approach
appears to yield improved short-term patency of the stenotic
lesion when compared with angioplasty alone,60 particularly
if they are heparin coated.61 It is currently unknown whether
the application of concepts borrowed from the cardiovascular
literature on drug-eluting stents62,63 to hemodialysis vascular
access is valid. Early animal models of antiproliferative
agents such as sirolimus and paclitaxel on grafts appear
promising64–66 but require further research. The ultimate role
of stent grafts within the ‘surveillance strategy’ has not yet
been defined. However, it appears they are susceptible to
damage by cannulation during intervention procedures,67
migration, and infection.67 Finally, their cost-effectiveness
has not been established.68
THE OUTCOMES
Tonelli et al.15 published a systematic review and meta-
analysis of available randomized controlled trials that have
evaluated Qa or duplex ultrasound surveillance in fistulae
(n¼ 4) and grafts (n¼ 7). The primary outcome was access
thrombosis. In addition to the small number of studies, their
quality was not high and statistical power was generally low.
Qa surveillance of fistulae was associated with a sig-
nificantly reduced relative risk of thrombosis, but no
significant improvement in fistula survival.15 The positive
result for fistula thrombosis should be considered tentative
given that it is based upon only four studies of 360 subjects.
By contrast, there was no evidence that graft surveillance by
flow or duplex ultrasound reduced thrombosis or improved
graft survival.
Some have argued that the randomized controlled trials
had inadequate power and would have shown a surveillance
benefit if they had included more patients.7 However,
given the foregoing factors that impair the success of
surveillance, it seems unlikely that larger studies would have
changed these negative outcomes. It is interesting that the
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Figure 7 |Graft blood flow (Qa) values measured within 1
month before thrombosis (132 thromboses in 108 grafts).
Many thromboses occurred at Qa values well above the Kidney
Disease Outcomes Quality Initiative (KDOQI) referral threshold of
o600ml/min.4 Database of ref. 50 was used to create the figure.
Kidney International (2012) 81, 132–142 137
WD Paulson et al.: Vascular access surveillance rev iew
paradigm-altering surveillance studies1,2 were also under-
powered. Nevertheless, the observed large improvements in
access outcomes would suggest the presence of bias.
A comparison of the results of nonrandomized versus
randomized studies further shows why randomized clinical
trials are needed to limit bias and confounding when
establishing guidelines. Allon13 reviewed six nonrandomized
studies of graft thrombosis that evaluated monitoring or
surveillance by various methods. These studies evaluated a
historical control period, followed by a monitoring or
surveillance period in which grafts were referred for
preemptive angioplasty when stenosis was suspected. All six
studies reported a substantial reduction in thrombosis rates
(Figure 8). In contrast, five randomized clinical trials found
no reduction in thrombosis.
IMPLICATIONS OF A SURVEILLANCE MANDATE
Despite the recent data from randomized controlled trials,
surveillance continues to be widely supported as a routine
part of access maintenance. For example, ESRD Networks in
the United States continue to promote access surveillance.
Moreover, the Centers for Medicare and Medicaid Services
(the US Government-sponsored insurance payer for dialysis)
has issued new rules69 that state ‘The [dialysis] facility must
have an ongoing program for vascular access monitoring and
surveillance (italics added) for early detection of failure and
to allow timely referral of patients for intervention when
indications of significant stenosis are present.’ This new
requirement is intended to promote continuous quality
improvement and reflect advances in technology and
standard care practices.
However, the Centers for Medicare and Medicaid Services
surveillance mandate has been criticized for not being
evidence based6,9 and may ultimately have the unintended
effect of limiting quality improvement. At the core of quality
improvement is ongoing research with reevaluation of
standard practices as new knowledge becomes available. In
the United States, however, the mandate has made it
impossible to conduct the studies (e.g., randomized con-
trolled trials) that are needed to determine the proper role of
surveillance. Specifically, because of this mandate, dialysis
units are unwilling to participate if patients are randomized
into a control group that consists solely of clinical
monitoring.7 Loss of such a control group also means that
we cannot properly study whether clinical monitoring has
similar, or possibly even better, outcomes when compared
with surveillance. If so, then failure to make this determina-
tion would lead to continued application of surveillance and
a missed opportunity to avoid unnecessary costs, interven-
tion procedures, and patient inconvenience.
Indeed, an important issue is the effect of the mandate on
the overall cost of care. The Centers for Medicare and
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Medicaid Services does not reimburse for the cost of
screening tests. Thus, dialysis units are expected to bear
these costs in the absence of strong evidence of efficacy. The
cost of surveillance ultimately depends on whether it can
prevent thrombosis and access loss, which is costly because of
unscheduled intervention procedures, catheter use, and
hospitalizations. There are limited data available on the costs
of access surveillance. Some have reported reduced costs with
Qa surveillance 70,71; however, these analyses were based on
observational or retrospective data and subject to the biases
inherent in such studies. Duplex ultrasound surveillance of
stenosis reduced costs in one randomized study,72 but not in
another.73 Randomized trials with no reduction in throm-
bosis have reported that surveillance was associated with
increased rates of intervention procedures,54,74,75 which
would be expected to increase costs. This result was
supported by a Canadian cost analysis that was based on a
simulation of results from two screening (surveillance)
strategies.76 They found that screening would not reduce
expected access-related costs under any clinically plausible
scenario, and many unnecessary angiography procedures
would be required. This Canadian analysis was performed in
an environment in which, unlike the USA, surveillance is not
mandated and reimbursement is applied through a universal
healthcare system. Thus, there is real concern that a
surveillance mandate will increase costs without yielding
significant benefits.
CURRENT OPTIONS
An ideal surveillance method should quickly, accurately,
noninvasively, and economically evaluate access anatomy
(eg., stenosis) and function. One basis of the surveillance
controversy is that the tests that were originally selected for
surveillance, Qa and VP, were surrogates for stenosis rather
than direct measurements. Although these tests are associated
with thrombosis, they lack the predictive accuracy needed to
be the sole basis for intervention referrals. Thus, Qa and VP
should be emphasized as ancillary tests to be used in
combination with information obtained from clinical
monitoring.
Qa and VP surveillance might improve outcomes if
measurements are taken more frequently. A key issue is that
patients have wide hemodynamic variation during dialysis;
hence, the reproducibility of measurements from session to
session is poor and may either fail to detect or falsely suggest
stenosis. Moreover, Qa and VP may change so rapidly that
there may be insufficient time to detect the change before
thrombosis. More frequent measurements would allow
calculation of average values that may neutralize hemody-
namic variation and might make it easier to detect rapid
changes in Qa or VP before thrombosis. However, Qa
measurements take significant time; hence, it is probably
impractical to increase measurement frequency unless there
is adequate reimbursement for staff time. In contrast, online
methods are available that allow frequently derived static VP
measurements.77 Our recommended approach to access
maintenance is listed in Table 1.
Duplex ultrasound has the advantage of directly visualiz-
ing stenosis while providing flow and velocity measurements
that help determine the physiological significance of stenosis.
Thus, ultrasound may avoid inaccuracies inherent in
surrogate measurements. However, the few available rando-
mized controlled trials have not established whether duplex
ultrasound can improve outcomes in grafts. Malik et al.78
reported that duplex ultrasound surveillance prolonged graft
survival, but their study is difficult to interpret because it
lacks documentation such as thrombosis rates. Dossabhoy
et al.72 found that hospitalizations and cost of care were
significantly reduced, but their study was a secondary analysis
of a randomized trial. They only found a trend of reduced
thrombosis, possibly because the study was underpowered.
Finally, Robbin et al.74 did not find a benefit; however, as
ultrasound was only applied every 4 months, measurements
might not have been frequent enough. Thus, further study by
properly designed and powered randomized controlled trials
with associated economic evaluations are needed to establish
the role of duplex ultrasound, which requires far more skill
than needed for Qa or VP measurements.
With regard to fistulae, although surveillance may
potentially reduce thrombosis,15 the major problem with
Table 1 | Recommendations for using Qa and VP measurements in access maintenance
1. Regular physical examination and clinical assessment are the keys to access maintenance.90–92
2. Measurements of Qa or static (or derived static) VP/MAP may be helpful ancillary tests that should be correlated with physical examination and
other clinical data. They are not suited to be the sole basis for intervention referrals.
3. Because hemodynamic variability causes large changes in Qa and VP/MAP, it is important to confirm changes in measurements before making
intervention referrals.
4. Fistula Qa o400–500ml/min and graft Qa o600ml/min are associated with stenosis; when such values are confirmed and correlated with clinical
monitoring information, they may assist in deciding whether to make an intervention referral.4
Note: a decrease in Qa should be433% to be statistically significant with Po0.05 (ref. 34); smaller decreases in Qa are often caused by hemodynamic
variation rather than an increase in stenosis.
5. Trend analysis is key to using static VP/MAP to detect a significant stenosis. The traditional threshold of VP/MAP 40.50 (or derived static
VP/MAP 40.55) is an unreliable indicator of stenosis and should not be the basis of an intervention referral.31
6. It may be best to direct surveillance resources to new accesses, which are most likely to thrombose and fail.50
7. Although it is often recommended that Qa and VP should be measured early in a dialysis session, there is no evidence to support this restriction.50
Abbreviations: MAP, mean arterial pressure; Qa, blood flow; VP, venous pressure.
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fistulae is the high maturation failure rate, which surveillance
cannot address.
As currently practiced, the ‘access surveillance strategy’
uses costly radiology resources and requires significant
patient time and inconvenience.76,79 We need to be able to
define and target high risk populations for surveillance, find a
validated test to predict those who will succeed or fail after an
intervention,80,81 and determine which interventions will
facilitate increased access patency without harm. Targeting
measurements to the newest accesses, which are most likely to
fail,50 appears to be a logical step. In contrast, attempts to
restore patency after thrombosis of new grafts may be short
lived and less successful than preemptive intervention.81–83
Optimal timing of both screening and intervention is critical
yet poorly established, and cannot be achieved without a
better understanding of the underlying condition. This
cannot occur without further research and validation, both
of which are at risk because of seemingly unjustified
mandates. It must be emphasized that all components of
the access–surveillance strategy need to be securely estab-
lished to be cost-effective.
Until further progress is made, monitoring by physical
examination should be emphasized as a cost-effective and
proven method to detect access abnormalities.84–89 However,
Besarab et al.7 have observed that nephrologists and dialysis
staff generally have limited knowledge of access anatomy and
function, and regular physical examination of accesses is
generally not carried out in dialysis units. This trend must be
reversed by emphasizing proper vascular access training and
clinical assessment in dialysis units.90 Given that vascular access
is the ‘Achilles heel’ of dialysis, it is understandable why
physicians might be eager to adopt new treatments or strategies
that seem hopeful without the necessary supportive evalua-
tion fromwell-designed and conducted studies. It is incumbent
on the nephrology community to incorporate a balanced,
evidence-based scientific approach to vascular access care.
CONCLUSION
We understand the limitations of surveillance much better
now than when the surveillance controversy began nearly two
decades ago. Evaluation of the surveillance strategy by
applying established criteria (e.g., World Health Organiza-
tion)27 shows little evidence that surveillance as currently
practiced (e.g., monthly Qa measurements) provides a
significant benefit. The current surveillance strategy (Figure 1)
fails at each component.
Physical examination and clinical assessment are the keys
to access maintenance and should be a part of the standard
care of dialysis patients. Qa and VP measurements may be
useful ancillary tests that can help confirm clinical suspicion
of stenosis or access dysfunction. The goal should be to
accurately identify those accesses that are most likely to
benefit from a preemptive intervention, while avoiding
procedures in accesses that are unlikely to benefit. However,
this remains an elusive goal that will only be reached when
properly designed studies are conducted.
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